Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05773001 · ClinicalTrials.gov registry record · Phase 1
Macrophage Regulation of Ozone-Induced Lung Inflammation
A Phase 1 study of SARS-CoV-2 Pneumonia, sponsored by Robert Tighe, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05773001 is a Phase 1 study of SARS-CoV-2 Pneumonia that is actively recruiting participants, run by Robert Tighe, MD. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05773001, a Phase 1 study of SARS-CoV-2 Pneumonia, is actively recruiting participants, sponsored by Robert Tighe, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.
Conditions Studied
Interventions
- DRUG Ozone
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-05-18 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05773001
The ClinicalTrials.gov registry entry for NCT05773001 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Tighe, MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV-2 Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which Ozone is the first listed.
NCT05773001 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05773001 about?
NCT05773001 is a clinical study titled "Macrophage Regulation of Ozone-Induced Lung Inflammation". The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.
What is the current status of trial NCT05773001?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2023-05-18. Estimated completion is 2028-05.
What conditions does trial NCT05773001 study?
This clinical trial studies the following conditions: SARS-CoV-2 Pneumonia.
What interventions are being tested in trial NCT05773001?
The interventions under investigation include: Ozone (DRUG).
Who is sponsoring clinical trial NCT05773001?
This trial is sponsored by Robert Tighe, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05773001 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.